Program
BAT5906
A development code. Also written as “BAT5906 injection”, “2.5mg of BAT5906” and “4.0mg of BAT5906”.
Its studies are mostly in Macular Degeneration · Macular Edema, led by Bio-Thera Solutions.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bio-Thera Solutions | 51 open or running | phase 3since Jun 13, 2022 | Nov 4, 2019 | Apr 30, 2027phase 3 · NCT07515079 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 4, 2019First study: phase 1 study in Macular DegenerationFirst studyNCT04151212 · 24 enrolled · China
- Jun 22, 20202 phase 2 studiesNCT05141994, NCT04772105
- Jun 13, 2022Phase 3 study in Macular DegenerationNCT05439629 · 488 enrolled · China
- Mar 23, 2026Phase 3 study in Diabetic Macular Edema (DME)NCT07515079 · 406 planned · China
Ahead
- Apr 30, 2027Primary completion: phase 3 study in Diabetic Macular Edema (DME)NCT07515079
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07515079Diabetic Macular Edema (DME) · China | 3 | Recruiting | Apr 30, 2027 | 406 |
| NCT05439629Macular Degeneration · China | 3 | Completed | Apr 22, 2025 | 488 |
| NCT05141994Wet Age-related Macular Degeneration · China | 2 | Completed | Sep 6, 2022 | 48 |
| NCT04772105Diabetic Macular Edema · China | 2 | Completed | Nov 6, 2023 | 60 |
| NCT04151212Macular Degeneration · China | 1 | Completed | Feb 28, 2021 | 24 |
How it is read
Names in the registry
- “BAT5906 injection”, 3 entries
- “2.5mg of BAT5906”, 2 entries
- “4.0mg of BAT5906”, 1 entry
- “4mg of BAT5906”, 1 entry
Codes read as this program: BAT5906.
Conditions, from the studies’ own filings
- Macular Degeneration, 3 studies
- Macular Edema, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.